BridgeBio Pharma SG&A Expenses 2018-2024 | BBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BridgeBio Pharma sg&a expenses from 2018 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BridgeBio Pharma sg&a expenses from 2018 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19B
Dr Reddy's Laboratories (RDY)	$12B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.1B
Supernus Pharmaceuticals (SUPN)	$2B
Taysha Gene Therapies (TSHA)	$434M
Personalis (PSNL)	$261M
Assembly Biosciences (ASMB)	$98M
Sol-Gel Technologies (SLGL)	$12M
Evoke Pharma (EVOK)	$7M
Teligent (TLGT)	$0M